WO2005001483A3 - Methods for diagnisis and differential diagnosis of dementia disorders - Google Patents

Methods for diagnisis and differential diagnosis of dementia disorders Download PDF

Info

Publication number
WO2005001483A3
WO2005001483A3 PCT/EP2004/006972 EP2004006972W WO2005001483A3 WO 2005001483 A3 WO2005001483 A3 WO 2005001483A3 EP 2004006972 W EP2004006972 W EP 2004006972W WO 2005001483 A3 WO2005001483 A3 WO 2005001483A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diagnisis
differential diagnosis
dementia disorders
diagnosis
Prior art date
Application number
PCT/EP2004/006972
Other languages
French (fr)
Other versions
WO2005001483A2 (en
Inventor
Markus Otto
Petra Steinacker
Original Assignee
Univ Goettingen Georg August
Markus Otto
Petra Steinacker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Goettingen Georg August, Markus Otto, Petra Steinacker filed Critical Univ Goettingen Georg August
Publication of WO2005001483A2 publication Critical patent/WO2005001483A2/en
Publication of WO2005001483A3 publication Critical patent/WO2005001483A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Abstract

The present invention relates to methods for the diagnosis of dementive disorders, especially Creutzfeldt-Jakob disease or Alzheimer's disease, wherein the amount of characteristic protein markers is used for diagnosis.
PCT/EP2004/006972 2003-06-27 2004-06-28 Methods for diagnisis and differential diagnosis of dementia disorders WO2005001483A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48305303P 2003-06-27 2003-06-27
US60/483,053 2003-06-27

Publications (2)

Publication Number Publication Date
WO2005001483A2 WO2005001483A2 (en) 2005-01-06
WO2005001483A3 true WO2005001483A3 (en) 2005-05-12

Family

ID=33552028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/006972 WO2005001483A2 (en) 2003-06-27 2004-06-28 Methods for diagnisis and differential diagnosis of dementia disorders

Country Status (1)

Country Link
WO (1) WO2005001483A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006223068A1 (en) 2005-03-14 2006-09-21 Bg Medicine, Inc. Methods for detecting Alzheimer's disease
CN107765015A (en) * 2017-09-08 2018-03-06 中国计量科学研究院 It is a kind of quantitatively to detect A β in brain tissue40The method of albumen

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002053A2 (en) * 1998-07-03 2000-01-13 Innogenetics N.V. Differential diagnosis of neurodegeneration
US6465195B2 (en) * 1999-12-30 2002-10-15 Washington University Predictive diagnostic for Alzheimer's disease
WO2004019043A2 (en) * 2002-08-23 2004-03-04 Bayer Healthcare Ag Polypeptide biomarkers for diagnosing alzheimer's disease
EP1469312A1 (en) * 2003-04-18 2004-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis of Alzheimer's disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002053A2 (en) * 1998-07-03 2000-01-13 Innogenetics N.V. Differential diagnosis of neurodegeneration
US6465195B2 (en) * 1999-12-30 2002-10-15 Washington University Predictive diagnostic for Alzheimer's disease
WO2004019043A2 (en) * 2002-08-23 2004-03-04 Bayer Healthcare Ag Polypeptide biomarkers for diagnosing alzheimer's disease
EP1469312A1 (en) * 2003-04-18 2004-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis of Alzheimer's disease

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CARRETTE O ET AL: "A NEW SENSITIVE AND HIGHLY SPECIFIC TEST FOR THE DIAGNOSIS OF ALZHEIMER DISEASE USING THE PROTEINCHIP TECHNOLOGY", FASEB JOURNAL (FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY), BETHESDA, US, vol. 17, no. 4/5, 11 April 2003 (2003-04-11), pages 4, XP008021866, ISSN: 0892-6638 *
CARRETTE O ET AL: "A PANEL OF CEREBROSPINAL FLUID POTENTIAL BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE", PROTEOMICS,, vol. 3, no. 8, August 2003 (2003-08-01), pages 1486 - 1494, XP008022060 *
KAPAKI E ET AL: "Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: A discrimination from Alzheimer's disease?", JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol. 71, no. 3, September 2001 (2001-09-01), pages 401 - 403, XP002305608, ISSN: 0022-3050 *
LEWCZUK PIOTR ET AL: "Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: Evidence of novel biomarkers in Alzheimer's disease.", BIOLOGICAL PSYCHIATRY, vol. 55, no. 5, 1 March 2004 (2004-03-01), pages 524 - 530, XP002305609, ISSN: 0006-3223 *
MADDALENA A ET AL: "Analysis of Abeta species and tau by protein chip technology in CSF of patients with Alzheimer's disease", ABSTRACTS OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 27, no. 1, 2001, pages 252, XP002254467, ISSN: 0190-5295 *
NILSSON CAROL L ET AL: "Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia", PEPTIDES (NEW YORK), vol. 22, no. 12, December 2001 (2001-12-01), pages 2105 - 2112, XP002305606, ISSN: 0196-9781 *
RIEMENSCHNEIDER M ET AL: "Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.", MOLECULAR PSYCHIATRY, vol. 8, no. 3, August 2003 (2003-08-01), pages 343 - 347, XP009039729, ISSN: 1359-4184 *
SHOJI M ET AL: "Combination assay of CSF Tau, A-beta-1-40 and A-beta-1-42(43) as a biochemical marker of Alzheimer's disease", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 158, no. 2, 30 June 1998 (1998-06-30), pages 134 - 140, XP002083581, ISSN: 0022-510X *
VANMECHELEN EUGEEN ET AL: "Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders", MECHANISMS OF AGEING AND DEVELOPMENT, vol. 122, no. 16, November 2001 (2001-11-01), pages 2005 - 2011, XP002305607, ISSN: 0047-6374 *
WILTFANG JENS ET AL: "beta-Amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.", ANNALS OF NEUROLOGY, vol. 54, no. 2, August 2003 (2003-08-01), pages 263 - 267, XP009020976, ISSN: 0364-5134 *

Also Published As

Publication number Publication date
WO2005001483A2 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
WO2005061545A3 (en) Nogoa antibodies for the treatment of alzheimer disease
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2004001421A3 (en) Method for the diagnosis and differential diagnosis of neurological diseases
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
HK1063012A1 (en) Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
WO2006124897A3 (en) Methods and compositions for improving cognition
WO2002085285A3 (en) Methods and reagents for regulating bone and cartilage formation
MXPA03010909A (en) Epothilone derivatives.
WO2004080376A3 (en) Hydroxyethylamine compounds having asp2 inhibitory activity for the treatment of alzheimer’s disease
WO2001075165A3 (en) Screening markers and methods for neurodegenerative disorders
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
WO2004082706A3 (en) Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders
AU2001236592A1 (en) Methods for diagnosis of alzheimer's disease
WO2003001182A3 (en) Homocysteinylated transthyretin
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
IL172229A (en) Use of pyrazolopyridines for the preparation of pharmaceutical compositions for improving perceptive cognition
WO2005001483A3 (en) Methods for diagnisis and differential diagnosis of dementia disorders
WO2004066940A3 (en) Compositions and methods containing substituted quinolines and substituted diphenylsulfones
ITMI20030778A1 (en) PROCEDURE FOR THE ENZYMATIC PREPARATION OF VANILLA AROMA.
IL172690A0 (en) Methods for the diagnosis and prognosis of alzheimer's disease
AU2003236714A1 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
WO2004005534A3 (en) Screening for alzheimer's disease
WO2007048034A3 (en) Use of androgens for the treatment of parkinson' s disease
WO2003000269A3 (en) Novel use for pde 10a inhibitors
WO2003031584A3 (en) Axon repair

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase